

STEREOREGULATION IN THE PREPARATION OF 1- AND 3-MONOSUBSTITUTED
1,2,3,4,6,7,12,12b-OCTAHYDROINDOLO[2,3-a]QUINOLIZINES.

MAURI LOUNASMAA*, REIJA JOKELA, BIRGIT TIRKKONEN AND
TARJA TAMMINEN

Laboratory for Organic and Bioorganic Chemistry,
Technical University of Helsinki, SF-02150 Espoo, Finland

(Received in UK 24 August 1989)


Abstract - Our recently developed method is successfully applied to the preparation of 1- and 3-monosubstituted 1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizines possessing the C(12b)H-C(1)H and C(12b)H-C(3)H relationship, respectively, cis or trans at will. Complete ¹³C NMR data are presented for the prepared compounds.

We recently developed a new synthetic method¹ which permits the preparation of 2-monosubstituted 1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizines possessing at will the C(12b)H-C(2)H cis or trans relationship.

Here we explore the applicability of the method to the preparation of 1- and 3-monosubstituted 1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizines possessing the C(12b)H-C(1)H and C(12b)H-C(3)H relationship, respectively, cis or trans at will.

RESULTS AND DISCUSSION


Alkylation of 3-ethylpyridine and methyl 3-pyridylacetate with tryptophyl bromide² afforded pyridinium salts 1 and 2, which, by NaBH₄ reduction and cyanide trapping,³⁻⁸ were transformed to α-aminonitriles 3 and 4, respectively. When 3 and 4 were treated with AcOH, indolo[2,3-a]quinolizidines 5 and 6 were obtained. A part of compounds 5 and 6 was transformed with di-t-butyl dicarbonate [(BOC)₂O]⁹⁻¹² to the corresponding BOC-protected indolo[2,3-a]quinolizidines 7 and 8 (Scheme 1).



Scheme 1

Catalytic hydrogenation (PtO₂) of compounds 5 and 6 led to compounds 9 (60%) and 11 (5%), and 10 (75%) and 12 (15%), respectively, of which the main products (compounds 9 and 10) possess the C(12b)H-C(3)H *cis* configuration. Compounds 9, 10, 11 and 12 were transformed with (BOC)₂O to the corresponding BOC-protected compounds 13, 14, 15 and 16, respectively. It was also verified that acid-induced cleavage (HCOOH) of the protective BOC-groups leads back to compounds 9, 10, 11 and 12 (Scheme 2).

By contrast, catalytic hydrogenation (PtO₂) of the BOC-protected compounds 7 and 8 led to compounds 13 (5%) and 15 (75%), and 14 (15%) and 16 (70%), respectively, of which the main products (compounds 15 and 16) possess the C(12b)H-C(3)H *trans* configuration. It was reverified (*vide supra*) that compounds 13, 14, 15 and 16 could be transformed to the corresponding non-protected compounds 9, 10, 11 and 12 by acid-induced cleavage (HCOOH) (Scheme 2).




Scheme 2

NaBH₄ reduction of pyridinium salt 1 yielded compound 17, which by H₂O₂ oxidation and modified Polonovski reaction^{6,13-15} was transformed to compound 18. A part of compound 18 was treated with (BOC)₂O to afford the corresponding BOC-protected compound 19 (Scheme 3).

Catalytic hydrogenation (PtO₂) of compound 18 led to compound 20 possessing the C(12b)H-C(1)H cis configuration. Traces of the corresponding C(12b)H-C(1)H trans derivative (compound 23; vide infra) were detected by TLC. Compound 20 was transformed by (BOC)₂O treatment to the corresponding BOC-protected compound 21, from which the non-protected compound 20 could be regenerated by acid-induced cleavage (HCOOH) (Scheme 4).

Again, in contrast to the above results, catalytic hydrogenation (PtO₂) of the BOC-protected compound 19 led to compound 22 possessing the C(12b)H-C(1)H trans configuration. Traces of the corresponding C(12b)H-C(1)H cis




Scheme 3

derivative (compound 21; *vide supra*) were detected by TLC. By acid-induced cleavage (HCOOH), compound 22 afforded the corresponding non-protected compound 23. It was also verified that the (BOC)₂O treatment transformed compound 23 back to the BOC-protected compound 22 (Scheme 4).

We also became interested in the behaviour of the indolo[2,3-*a*]-quinolizidine skeleton possessing an exocyclic double bond at C-3 (present in many indole alkaloids) in the above described reduction conditions. For the compounds to be tested we chose (±)-deplancheine 24¹⁶ and its BOC-protected counterpart 25, easily prepared from 24 by (BOC)₂O treatment (Scheme 5).

Catalytic hydrogenation (PtO₂) of (±)-deplancheine 24 led almost exclusively to compound 11 possessing the C(12b)H-C(3)H *trans* configuration, whereas the same treatment of compound 25 afforded an equimolar mixture of compounds 13 and 15 possessing the C(12b)H-C(3)H *cis* and *trans* configurations, respectively (Scheme 5). Thus, even in these




Scheme 4

cases the presence or absence of the BOC group in the indolo[2,3-*a*]quinolizidine skeleton has its effect on the stereochemistry of the resulting products, though in the opposite way to that described above.

The ¹³C NMR data of compounds 4, 6, 8, 10, 12, 14, 16, 17, 18, 19, 21, 22, 24 and 25 are given in Fig. 1. For those of compounds 3, 5, 7, 9, 11, 13 and 15, see Ref. 6 (compounds 2, 3, 5, 8, 9, 11 and 12, respectively) and for those of compounds 20 and 23, see Ref. 17 (compounds 2 and 1, respectively).

Comparison of the chemical shifts found for compounds 6, 8, 10, 12, 14, 16, 18, 19, 21, 22, 24 and 25 with those given earlier,^{1,6,17} taking into account the conformational considerations relevant for indolo[2,3-*a*]quinolizidines,^{1,5} provides clear evidence of the stereostructures depicted in the formulae. Drastic changes are seen in the shift values for C(6), C(7a), C(9), C(10), C(11) and C(12a) in the BOC-protected indolo[2,3-*a*]quinolizidines 8, 14, 16, 19, 21, 22 and 25 relative to their non-protected counterparts 6, 10, 12, 18, 20, 23 and 24. The shift value of ~

47 ppm found for C(6) in the spectra of compounds 8, 16 and 25, and that of 51.3 ppm found in the spectrum of compound 14, are in agreement with the earlier results.⁶



Scheme 5

The clear difference between the C(6) signals (51.8 vs. 42.9 ppm) in the spectra of compounds 21 and 22 indicates a pronounced change in the contribution of different conformations of the indolo[2,3-*a*]quinolizidine skeleton to the conformational equilibrium of these two compounds. For a more detailed general discussion of this subject, see Refs. 1, 5 and 6.

CONCLUSIONS

The results clearly demonstrate the value of our method for the stereoselective preparation of 1- and 3-monosubstituted 1,2,3,4,6,7,12,12b-octahydroindolo[2,3-*a*]quinolizines with the C(12b)H-C(1)H and C(12b)H-C(3)H relationship, respectively, *cis* or *trans* at will.




Fig. 1

EXPERIMENTAL

IR spectra were recorded with a Perkin-Elmer 700 spectrophotometer in CHCl_3 , if not otherwise stated. ^1H and ^{13}C NMR spectra were measured with a Jeol JNM-FX 60 spectrometer working at 59.80 MHz (^1H NMR) and 15.04 MHz (^{13}C NMR). The spectra were recorded in CDCl_3 . Chemical shift data are given in ppm downfield from TMS. Abbreviations s, d, t, m, br and def are used to designate singlet, doublet, triplet, multiplet, broad and deformed, respectively. For the ^{13}C NMR data of compounds 3, 5, 7, 9, 11, 13 and 15, see Ref. 6 (compounds 2, 3, 5, 8, 9, 11 and 12, respectively) and for the data of compounds 20 and 23, see Ref. 17 (compounds 2 and 1, respectively). For the other ^{13}C NMR data, see Fig. 1. Mass spectrometry (EIMS and HRMS) was done on a Jeol DX 303/DA 5000 instrument.

Preparation of compound 3

Hydrochloric acid (6 N, 1.5 ml) was added dropwise to a stirred solution of KCN (1.13 g, 17.4 mmol) in H_2O (1.5 ml), layered with Et_2O (9 ml), and kept at 0°C (Ar atm). Pyridinium salt 1¹⁷ (1.00 g, 3.02 mmol) prepared by alkylation of 3-ethylpyridine with tryptophyl bromide², was dissolved in MeOH (2.4 ml), and NaBH_4 (127 mg, 3.32 mmol) was added during 0.5 h. The mixture was stirred at rt for 3.5 h. The Et_2O layer was separated and the aqueous layer was extracted several times with Et_2O . The combined ethereal extracts were dried (Na_2SO_4) and evaporated to give compound 3.

Y. 90%. Viscous oil.

Analytical data were identical with those described earlier.⁶

Preparation of compound 4

Reaction of pyridinium salt 2^{11,18} (1.13 g, 3.02 mmol), prepared by alkylation of methyl 3-pyridylacetate with tryptophyl bromide², with KCN (1.13 g, 17.4 mmol) and NaBH_4 (127 mg, 3.32 mmol) using the procedure described for compound 3 (*vide supra*) afforded compound 4.

Y. 92%. Amorphous material.

IR: 3450 (NH), 1740 (C=O).

^1H NMR: 3.63 (3H, s, $-\text{CO}_2\text{CH}_3$), 5.57 (1H, br s, H-4'), 6.89 (1H, d, $J=1.8$ Hz, H-2), 7.17-7.65 (4H, m, arom. H), 8.47 (1H, br s, NH).

MS: 323 (M^+), 296, 237, 193, 179, 166, 165, 151, 144 (100%), 130; exact mass: 323.1624 (calc. for $\text{C}_{19}\text{H}_{21}\text{N}_3\text{O}_2$: 323.1634).

Preparation of compound 5

Compound 3 (0.76 g, 2.72 mmol) was dissolved in 80 ml of 50% HOAc and the solution was stirred at rt (N₂ atm) for 3 d. It was then evaporated and shaken with 2N Na₂CO₃. Extraction with CH₂Cl₂ and drying (Na₂SO₄) yielded the crude product of 5^{6,19}, which was purified by column chromatography (silica, CH₂Cl₂-MeOH, 95:5).

Y. 45%. Mp. 146-148°C (EtOH) (lit. Mp. 147-148°C⁴, 146-148°C⁶, 143-145°C²⁰).

Analytical data were identical with those described earlier.⁶

Preparation of compound 6

Compound 4 (0.88 g, 2.72 mmol) was dissolved in 90 ml of 50% HOAc and the solution was stirred at rt (Ar-atm) for 23 h. Usual work-up afforded the crude product of compound 6¹⁸, which was purified by column chromatography (alumina, CH₂Cl₂-MeOH, 99.5:0.5).

Y. 42%. Mp. 133°C (MeOH) (lit.¹⁸ amorphous material).

IR: 3450 (NH), 1730 (C=O).

¹H NMR: 3.69 (3H, s, -CO₂CH₃), 5.64 (1H, br s, H-2), 6.99-7.54 (4H, m, arom. H), 8.14 (1H, br s, NH).

MS: 228 (M⁺), 255, 277, 270 (200%), 289; exact mass: 228.2528 (calc. for C₁₈H₂₀N₂O₂: 296.1525).

Preparation of compound 7

To compound 5 (116 mg, 0.46 mmol) in 1 ml of abs. CH₂Cl₂ was added *p*-dimethylamino pyridine (DMAP) (6 mg, 0.1 equiv.) and di-*t*-butyl dicarbonate [(BOC)₂O] (120 mg, 1.2 equiv.) with stirring at rt (Ar atm). After 2 h the mixture was evaporated and purified by column chromatography (silica, CH₂Cl₂-MeOH-Et₃N, 97.75:2:0.25) to afford compound 7.

Y. 90%. Viscous oil.

Analytical data were identical with those described earlier.⁶

Preparation of compound 8

Reaction of compound 6 (166 mg, 0.56 mmol) with DMAP (7 mg, 0.1 equiv.) and (BOC)₂O (220 mg, 1.8 equiv.) using the procedure described for compound 7 (*vide supra*) gave the crude product of 8, which was purified by column chromatography (silica, CH₂Cl₂-MeOH-Et₃N, 99:0.75:0.25).

Y. 85%. Viscous oil.

IR: 1725 (C=O).

¹H NMR: 1.66 (9H, s, -C(CH₃)₃), 3.69 (3H, s, -CO₂CH₃), 5.67 (1H, br s, H-2), 7.14-7.52 (3H, m, H-8, 9, 10), 8.07 (1H, m, H-11).

MS: 396 (M^+), 339, 295, 281, 214, 170 (100%), 169, 168; exact mass: 396.2058 (calc. for $C_{23}H_{28}N_2O_4$: 396.2049).

Preparation of compounds 9 and 11

Hydrogenation (MeOH, PtO_2 , 25 h) of compound 5 (230 mg, 0.91 mmol) followed by separation by column chromatography (silica, CH_2Cl_2 -MeOH, 95:5) yielded compounds 9 and 11.

Compound 9:

Y. 60%. Viscous oil.

Analytical data were identical with those described earlier.^{6,17,21,22}

Compound 11:

Y. 5%. Mp. 159-161°C (EtOH) (lit. Mp. 159-161°C⁶, 160-161°C²², 157°C²³).

Analytical data were identical with those described earlier.^{6,17,21-23}

Preparation of compounds 10 and 12

Hydrogenation (MeOH, PtO_2 , 25 h) of compound 6 (224 mg, 0.76 mmol) followed by separation by column chromatography (silica, CH_2Cl_2 -MeOH, 97:3) yielded compounds 10 and 12.

Compound 10:

Y. 75%. Mp. 180-182°C (MeOH).

Analytical data were identical with those described earlier.¹¹

Compound 12:

Y. 15%. Mp. 164-165°C (MeOH) (lit.¹⁸ Mp. 168°C).

IR: 3420 (NH), 1740 (C=O).

¹H NMR: 3.68 (3H, s, $-CO_2CH_3$), 7.00-7.55 (4H, m, arom. H), 7.81 (1H, br s, NH).

MS 298 (M^+), 297 (100%), 283, 267, 225, 197, 184, 170, 169; exact mass: 298.1683 (calc. for $C_{18}H_{22}N_2O_2$: 298.1681).

Preparation of compound 13

Reaction of compound 9 (133 mg, 0.52 mmol) with DMAP (6 mg, 0.1 equiv.) and $(BOC)_2O$ (204 mg, 1.8 equiv.) using the procedure described for compound 7 (*vide supra*) afforded the crude product of compound 13, which was purified by column chromatography (silica, CH_2Cl_2 -MeOH, 97:3).

Y. 90%. Viscous oil.

Analytical data were identical with those described earlier.⁶

Preparation of compound 14

Reaction of compound 10 (90 mg, 0.30 mmol) with DMAP (4 mg, 0.1 equiv.) and (BOC)₂O (120 mg, 1.8 equiv.) using the procedure described for compound 7 (vide supra) gave the crude product of compound 14, which was purified by column chromatography (silica, CH₂Cl₂-MeOH, 99:1).

Y. 90%. Viscous oil.

IR: 1730 (C=O).

¹H NMR: 1.64 (9H, s, -C(CH₃)₃), 3.66 (3H, s, -CO₂CH₃), 7.13-7.50 (3H, m, H-8, 9, 10), 8.08 (1H, m, H-11).

MS: 398 (M⁺), 342, 341 (100%), 297, 269, 170, 169; exact mass: 398.2219 (calc. for C₂₃H₃₀N₂O₄: 398.2206).

Preparation of compound 15

Reaction of compound 11 (35 mg, 0.14 mmol) with DMAP (1.7 mg, 0.1 equiv.) and (BOC)₂O (53 mg, 1.8 equiv.) using the procedure described for compound 7 (vide supra) afforded the crude product of compound 15, which was purified by flash chromatography (alumina, CH₂Cl₂).

Y. 85%. Viscous oil.

Analytical data were identical with those described earlier.⁶

Preparation of compound 16

Reaction of compound 12 (22 mg, 0.08 mmol) with DMAP (0.8 mg, 0.1 equiv.) and (BOC)₂O (28 mg, 1.8 equiv.) using the procedure described for compound 7 (vide supra) afforded the crude product of compound 16, which was purified by flash chromatography (alumina, CH₂Cl₂).

Y. 50%. Viscous oil.

IR: 1730 (C=O).

¹H NMR: 1.65 (9H, s, -C(CH₃)₃), 3.68 (3H, s, -CO₂CH₃), 7.13-7.40 (3H, m, H-8, 9, 10), 8.09 (1H, m, H-11).

MS: 398 (M⁺), 342, 341 (100%), 297, 269, 170, 169; exact mass: 398.2232 (calc. for C₂₃H₃₀N₂O₄: 398.2206).

Preparation of compounds 13 and 15

Hydrogenation (MeOH, PtO₂, 17 h) of compound 7 (150 mg, 0.43 mmol) followed by separation by column chromatography (silica, CH₂Cl₂-MeOH, 97:3) afforded compounds 13 and 15.

Compound 13:

Y. 5%. Viscous oil.

Analytical data were identical with those of compound 13 described above.

Compound 15:

Y. 75%. Viscous oil.

Analytical data were identical with those of compound 15 described above.

Preparation of compounds 14 and 16

Hydrogenation (MeOH, PtO₂, 22 h) of compound 8 (160 mg, 0.40 mmol) followed by separation by column chromatography (silica, CH₂Cl₂-MeOH, 99:1) afforded compounds 14 and 16.

Compound 14:

Y. 15%. Viscous oil.

Analytical data were identical with those of compound 14 described above.

Compound 16:

Y. 70%. Viscous oil.

Analytical data were identical with those of compound 16 described above.

Preparation of compounds 9 and 11 by BOC cleavage

Compound 13 or 15 (88 mg, 0.25 mmol) was dissolved in HCOOH (3.7 ml). The reaction mixture was stirred for 28 h at rt (Ar atm). It was then evaporated and shaken with 10% aq. Na₂CO₃. Extraction with CH₂Cl₂ and drying (Na₂SO₄) afforded the crude product of compound 9 or compound 11, respectively, which was purified by column chromatography (silica, CH₂Cl₂-MeOH, 95:5).

Compound 9:

Y. 80%. Viscous oil.

Analytical data were identical with those described earlier.^{6,17,21,22}

Compound 11:

Y. 80%. Mp. 159-161°C (EtOH) (lit. Mp. 159-161°C⁶, 160-161°C²², 157°C²³).

Analytical data were identical with those described earlier.^{6,17,21-23}

Preparation of compounds 10 and 12 by BOC cleavage

Treatment of compounds 14 and 16 (88 mg, 0.22 mmol) with HCOOH following the procedure described for compounds 9 and 11 (*vide supra*) gave the crude products of compounds 10 and 12, respectively, which were purified by preparative TLC (silica, CH₂Cl₂-MeOH, 90:10).

Compound 10:

Y. 80%. Mp. 180-182°C (MeOH).

Analytical data were identical with those described earlier.¹¹

Compound 12:

Y. 80%. Mp. 164-165°C (MeOH).

Analytical data were identical with those of compound 12 described above.

Preparation of compound 17

Pyridinium salt 1 (3.00 g, 9.06 mmol) (*vide supra*) was dissolved in MeOH:H₂O (9:1, 150 ml), and NaBH₄ (4.13 g, 0.11 mol) was added during 30 min at 0°C (Ar atm). The mixture was stirred for 4 h at rt. Usual work-up afforded compound 17.

Y. 99%. Mp. 122°C (benzene-hexane) (lit.²⁴ Mp. 122°C).

IR (KBr): 3440 (NH).

¹H NMR: 1.02 (3H, t, J=7.2 Hz, -CH₂CH₃), 5.47 (1H, br s, H-4'), 6.92 (1H, d, J=1.8 Hz, H-2), 7.18-7.68 (4H, m, arom. H), 8.54 (1H, br s, NH).

MS: 254 (M⁺), 124 (100%); exact mass: 254.1775 (calc. for C₁₇H₂₂N₂: 254.1783).

Preparation of compound 18

Compound 17 (1.51 g, 5.95 mmol) was reacted with H₂O₂ (30%, 1.7 ml) in CHCl₃:MeOH (1:1, 30 ml) to afford after the usual work-up the corresponding N-oxide (1.59 g, 99%). The N-oxide in trifluoroacetic acid (32 ml) was stirred at 0°C (Ar atm) and trifluoroacetic anhydride (8 ml, 9.6 equiv.) was added during 15 min. After 1 h at rt, 2N HCl (48 ml) was added carefully and the mixture was kept at 70°C for 20 min. Neutralization with NaHCO₃ (s) in CH₂Cl₂ followed by usual work-up and purification by flash chromatography (alumina, CH₂Cl₂) afforded compound 18.

Y. 20%. Mp. 108-112°C (benzene-hexane) (lit.²⁵ Mp. 115-116°C).

IR: 3480 (NH).

¹H NMR: 1.13 (3H, t, J=7.4 Hz, -CH₂CH₃), 4.57 (1H, m, H-12b), 5.60 (1H, m, H-2), 7.00-7.55 (4H, arom. H), 8.17 (1H, br s, NH).

MS: 252 (M⁺, 100%), 251, 237, 223; exact mass: 252.1601 (calc. for C₁₇H₂₀N₂: 252.1626).

Preparation of compound 19

Reaction of compound 18 (34 mg, 0.14 mmol) with DMAP (2 mg, 0.1 equiv.) and (BOC)₂O (53 mg, 1.8 equiv.) following the procedure described for compound 7 (*vide supra*) afforded the crude product of compound 19, which was purified by column chromatography (alumina, CH₂Cl₂).

Y. 90%. Viscous oil.

IR: 1730 (C=O).

^1H NMR: 0.80 (3H, t, $J=7.3$ Hz, CH_2CH_3), 1.66 (9H, s, $-\text{C}(\text{CH}_3)_3$), 5.51 (1H, m, H-2), 7.14-7.41 (3H, m, H-8, 9, 10), 8.11 (1H, m, H-11).
MS: 352 (M^+), 323, 295 (100%), 267, 251; exact mass: 352.2168 (calc. for $\text{C}_{22}\text{H}_{28}\text{N}_2\text{O}_2$: 352.2151).

Preparation of compound 20

Hydrogenation (MeOH, PtO_2 , 5h) of compound 18 (61 mg, 0.24 mmol) afforded after usual work-up compound 20.

Y. 90%. Mp. 216-217°C (benzene-hexane) (lit. Mp. 116-119°C²¹, 61-70°C²⁶).

Analytical data were identical with those described earlier.¹⁷

Preparation of compound 21

Reaction of compound 20 (41 mg, 0.16 mmol) with DMAP (2 mg, 0.1 equiv.) and $(\text{BOC})_2\text{O}$ (64 mg, 1.8 equiv.) following the procedure described for compound 7 (*vide supra*) afforded the crude product of compound 21, which was purified by flash chromatography (alumina, CH_2Cl_2 -MeOH, 99.5:0.5).

Y. 80%. Viscous oil.

IR: 1720 (C=O).

^1H NMR: 0.75 (3H, def, $-\text{CH}_2\text{CH}_3$), 1.65 (9H, s, $-\text{C}(\text{CH}_3)_3$), 3.74 (1H, m, H-12b), 7.13-7.40 (3H, m, H-8, 9, 10), 8.06 (1H, m, H-11).

MS: 354 (M^+), 298, 297 (100%), 253, 170, 169; exact mass: 354.2315 (calc. for $\text{C}_{22}\text{H}_{30}\text{N}_2\text{O}_2$: 354.2307).

Preparation of compound 20 by BOC cleavage

Treatment of compound 21 (32 mg, 0.09 mmol) with HCOOH following the procedure described for compounds 9 and 11 (*vide supra*) afforded after normal work-up compound 20.

Y. 95%. Mp. 216-217°C (benzene-hexane) (lit. Mp. 116-119°C²¹, 61-70°C²⁶).

Analytical data were identical with those of compound 20 described above.

Preparation of compound 22

Hydrogenation (MeOH, PtO_2 , 60 h) of compound 19 (83 mg, 0.24 mmol) followed by purification by flash chromatography (alumina, CH_2Cl_2) afforded compound 22.

Y. 35%. Viscous oil.

IR: 1730 (C=O).

^1H NMR: 0.90 (3H, def, $-\text{CH}_2\text{CH}_3$), 1.66 (9H, s, $-\text{C}(\text{CH}_3)_3$) 4.64 (1H, m, H-12b), 7.11 - 7.41 (3H, m, H-8, 9, 10), 8.07 (1H, m, H-11).

MS: 354 (M^+), 298, 297 (100%), 253, 170, 169; exact mass: 354.2346 (calc. for $C_{22}H_{30}N_2O_2$: 354.2307).

Preparation of compound 23 by BOC cleavage

Treatment of compound 22 (32 mg, 0.09 mmol) with HCOOH following the procedure described for compounds 9 and 11 (*vide supra*) gave after normal work-up compound 23.

Y. 95%. Mp. 123-125°C (benzene-hexane) (lit. Mp. 90-93°C²¹, 113-114°C²⁶).

Analytical data were identical with those described earlier.¹⁷

Preparation of compound 22 from compound 23

Reaction of compound 23 (23 mg, 0.09 mmol) with DMAP (1.1 mg, 0.1 equiv.) and (BOC)₂O (35 mg, 1.8 equiv.) following the procedure described for compound 7 (*vide supra*) afforded the crude product of compound 22, which was purified by flash chromatography (alumina, CH₂Cl₂).

Y. 45%. Viscous oil.

Analytical data were identical with those of compound 22 described above.

Preparation of compound 11 from (±)-deplancheine 24

Hydrogenation (MeOH, PtO₂, 20 h) of (±)-deplancheine 24¹⁶ (21 mg, 0.08 mmol) gave after normal work-up compound 11.

Y. 99%. Mp. 159-161°C (EtOH) (lit. Mp. 159-161°C⁶, 160-161°C²², 157°C²³).

Analytical data were identical with those described earlier.^{17,21-23}

Preparation of compound 25

Reaction of (±)-deplancheine 24¹⁶ (28 mg, 0.11 mmol) with DMAP (1.4 mg, 0.1 equiv.) and (BOC)₂O (44 mg, 1.8 equiv.) following the procedure described for compound 7 gave compound 25. The crude product was purified by flash chromatography (alumina, CH₂Cl₂).

Y. 75%. Viscous oil.

IR: 1735 (C=O).

¹H NMR: 1.68 (9H, s, -C(CH₃)₃), 4.41 (1H m, H-12b), 5.34 (1H, m, =CHCH₃), 7.13-7.50 (3H, m, H-8,9,10), 8.11 (1H, m, H-11).

MS: 352 (M^+), 296, 295 (100%), 281, 251, 170, 169; exact mass: 352.2162 (calc. for $C_{22}H_{28}N_2O_2$: 352.2151).

Preparation of compounds 13 and 15 from compound 25

Hydrogenation (MeOH, PtO₂, 20 h) of compound 25 (29 mg, 0.08 mmol)

followed by purification by flash chromatography (alumina, CH₂Cl₂) afforded a 1:1 mixture of compounds 13 and 15.

Y. 50%.

For the analytical data, see above.

REFERENCES AND NOTES

1. Lounasmaa, M.; Jokela, R. Tetrahedron 1989, 45, 3975.
2. Hoshino, T.; Shimodaira, K. Liebigs Ann. Chem. 1935, 520, 19.
3. Fry, E.M. J. Org. Chem. 1964, 29, 1647.
4. Fry, E.M.; Beisler, J.A. J. Org. Chem. 1970, 35, 2809.
5. Lounasmaa, M. in "Studies in Natural Products Chemistry", ed. Attatur-Rahman, Vol. 1, Stereoselective Synthesis (Part A), Elsevier, Amsterdam, 1988, pp. 89-122.
6. Tamminen, T.; Jokela, R.; Tirkkonen, B.; Lounasmaa, M. Tetrahedron 1989, 45, 2683.
7. Grierson, D.S.; Harris, M.; Husson, H.-P. J. Am. Chem. Soc. 1980, 102, 1064.
8. Jokela, R.; Tamminen T.; Lounasmaa, M. Heterocycles 1985, 23, 1707.
9. Grierson, D.S.; Harris, M.; Husson, H.-P. Tetrahedron 1983, 39, 3683.
10. Lounasmaa, M.; Karvinen, E.; Koskinen, A.; Jokela, R. Tetrahedron 1987, 43, 2135.
11. Jokela, R.; Karvinen, E.; Tolvanen, A.; Lounasmaa, M. Tetrahedron 1988, 44, 2367.
12. Lounasmaa, M.; Jokela, R. Heterocycles 1986, 24, 1663.
13. Cavé, A.; Kan-Fan, C.; Potier, P.; Le Men, J. Tetrahedron 1967, 23, 4681.
14. Potier, P. Rev. Latinoamer. Quim. 1978, 9, 47.
15. Lounasmaa, M.; Koskinen, A. Heterocycles 1984, 22, 1591.
16. Hämeilä, M.; Lounasmaa, M. Acta Chem. Scand. 1981, B35, 217.
17. Lounasmaa, M.; Jokela, R.; Tamminen, T. Heterocycles 1985, 23, 1367. See also, Ref. 6, Note 15 and Ref. 11, Note 15.
18. Thal, C.; Imbert, T.; Husson, H.-P.; Potier, P. Bull. Soc. Chim. France 1973, 2010.
19. Jokela, R.; Juntunen, A.; Lounasmaa, M. Planta Medica 1987, 386.
20. Wenkert, E.; Massy-Westropp, R.A.; Lewis, R.G. J. Am. Chem. Soc. 1962, 84, 3732.
21. Wenkert, E.; Wickberg, B. J. Am. Chem. Soc. 1962, 84, 4914.
22. Yamanaka, E.; Narushima, M.; Inukai, K.; Sakai, S.-I. Chem. Pharm. Bull. 1986, 34, 77.
23. Massiot, G.; Oliveira, F.S.; Lévy, J. Bull. Soc. Chim. France II 1982, 185.
24. Grierson, D.S.; Vuilhorgne, M.; Husson, H.-P. J. Org. Chem. 1982, 47, 4439.
25. Chevotot, L.; Husson, A.; Kan-Fan, C.; Husson, H.-P.; Potier, P. Bull. Soc. Chim. France 1976, 1222.
26. Laronze, J.Y.; Laronze, J.; Caron, B.; Lévy, J.; Le Men, J. Bull. Soc. Chim. France 1977, 1207.